Accudial Pharmaceutical, Inc. Signs Distribution Agreement with BroadMed

Accudial Pharmaceutical, Inc. and BroadMed S.A.L, with headquarters in Lebanon signed an agreement for BroadMed to distribute Children’s AccuDial® analgesic, allergy, cough and cold medications that have been approved by Health Canada. BroadMed anticipates distribution of the AccuDial® brand products in twenty countries in the Middle East and North Africa (“MENA”).“The demand for quality over-the-counter medication crosses all boarders and AccuDial’s® weight-based dosing is the most accurate way to calculate and administer those medications,” said Robert Terwilliger, Chairman and CEO of Accudial Pharmaceutical, Inc. “This opens up a market that is 50% larger than the United States. The population of these two regions is approximately 459 million people with approximately 142 million being children. That’s more than twice the number of children in the United States.”“BroadMed is very happy to be able to offer Children’s AccuDial® directly to our wholesalers and retailers,” adds BroadMed’s Chairman and General Manager Khalil Afsh, M.D. “Children’s AccuDial® is the only medication that provides a patented weight-based dosing solution on the bottle label that addresses the need to properly dose our children.”The distribution agreement is an exclusive agreement for countries of the MENA region. Both companies are looking forward to broadening the reach of administering weight-based dosing to children. Children’s AccuDial® features a revolutionary, two-part, patented label system. A parent or caregiver rotates the label until their child’s weight appears in the viewing window. Below the child’s weight is the proper amount of medication. A caregiver then pours the liquid into the calibrated dosing device (included in the package) to the exact measurement, and the child receives the correct dose of medication. No second guessing; it’s all medical science.